Press Releases Latest Sep 26, 2022 Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update Press Releases Year None2022202120202019201820172016201520142013 Sep 26, 2022 Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update Sep 19, 2022 Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference Sep 12, 2022 Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Aug 02, 2022 Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference Jul 28, 2022 Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens Jul 27, 2022 Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Jul 14, 2022 Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update Jul 14, 2022 Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies Jul 13, 2022 Theratechnologies Announces Binding Commitment for a Non-Dilutive Term Loan of up to $100 million from Marathon Asset Management Jul 12, 2022 CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 1 - 10 of 292
Sep 26, 2022 Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update
Sep 26, 2022 Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update
Sep 12, 2022 Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth
Jul 28, 2022 Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens
Jul 27, 2022 Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement
Jul 14, 2022 Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update
Jul 14, 2022 Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies
Jul 13, 2022 Theratechnologies Announces Binding Commitment for a Non-Dilutive Term Loan of up to $100 million from Marathon Asset Management
Jul 12, 2022 CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal
